Juno Therapeutics, Inc. (NASDAQ:JUNO)‘s stock had its “in-line” rating reaffirmed by stock analysts at Leerink Swann in a research note issued to investors on Thursday, November 2nd. They presently have a $56.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $34.00. Leerink Swann’s target price suggests a potential downside of 4.71% from the company’s previous close.
JUNO has been the topic of several other research reports. SunTrust Banks, Inc. upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. Morgan Stanley reiterated an “equal weight” rating and issued a $43.00 target price (up previously from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Cowen and Company restated a “buy” rating and issued a $49.00 price target on shares of Juno Therapeutics in a research report on Friday, October 27th. Vetr upgraded shares of Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price target on the stock in a research report on Monday, August 14th. Finally, Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 28th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $44.20.
Shares of Juno Therapeutics (NASDAQ JUNO) opened at $58.77 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $61.59.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.07. The business had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. Juno Therapeutics’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.57) EPS. equities research analysts expect that Juno Therapeutics will post -4.02 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Juno Therapeutics, Inc. (JUNO) Receives “In-Line” Rating from Leerink Swann” was first reported by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://baseballnewssource.com/markets/leerink-swann-reiterates-in-line-rating-for-juno-therapeutics-inc-juno/1752246.html.
In related news, EVP Robert Azelby sold 12,869 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $39.95, for a total transaction of $514,116.55. Following the completion of the sale, the executive vice president now directly owns 50,289 shares of the company’s stock, valued at $2,009,045.55. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Bernard J. Cassidy sold 28,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the sale, the general counsel now directly owns 55,970 shares of the company’s stock, valued at $2,514,172.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,670 shares of company stock valued at $3,553,777. Insiders own 15.26% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. California Public Employees Retirement System boosted its holdings in shares of Juno Therapeutics by 2.7% in the third quarter. California Public Employees Retirement System now owns 73,100 shares of the biopharmaceutical company’s stock valued at $3,279,000 after buying an additional 1,900 shares during the period. Capital Bank & Trust Co acquired a new position in Juno Therapeutics during the third quarter worth $8,517,000. Orbimed Advisors LLC boosted its holdings in Juno Therapeutics by 123.1% during the third quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock worth $91,587,000 after purchasing an additional 1,126,400 shares during the last quarter. Capital International Investors acquired a new position in Juno Therapeutics during the third quarter worth $256,339,000. Finally, Capital Guardian Trust Co. acquired a new position in Juno Therapeutics during the third quarter worth $37,400,000. Hedge funds and other institutional investors own 66.96% of the company’s stock.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with our FREE daily email newsletter.